Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Leukemia

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 208 articles:
HTML format



Single Articles


    May 2025
  1. SCARADAVOU A
    Cord blood transplants: Advancing leukaemia treatments and addressing health disparities.
    Br J Haematol. 2025;206:1312-1314.
    PubMed     Abstract available


  2. ZHENG Z, Wang W, Feng M, Chen X, et al
    The mechanism of EZH2/H3K27me3 downregulating CXCL10 to affect CD8(+) T cell exhaustion to participate in the transformation from myelodysplastic syndrome to acute myeloid leukaemia.
    Br J Haematol. 2025;206:1335-1349.
    PubMed     Abstract available


  3. VICENTE-GARCES C, Fernandez G, Esperanza-Cebollada E, Richarte-Franques M, et al
    RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia.
    Br J Haematol. 2025;206:1355-1365.
    PubMed     Abstract available


  4. LIU J, Zhao XS, Chang YJ, Qin YZ, et al
    Monitoring the KMT2A gene post-chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:1418-1429.
    PubMed     Abstract available


  5. SUTTORP M, Sembill S, Lensker P, Hildebrand V, et al
    Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting.
    Br J Haematol. 2025;206:1397-1405.
    PubMed     Abstract available


  6. STASIK S, Eckardt JN, Rollig C, Baldus CD, et al
    The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML.
    Br J Haematol. 2025;206:1373-1379.
    PubMed     Abstract available


    April 2025
  7. ZHAO C, Xiao MY, Zhang F, Bai L, et al
    Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2025;206:1165-1172.
    PubMed     Abstract available


  8. CONNERTY P, Xie J, El-Najjar F, Trahair TN, et al
    Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in xenograft models of paediatric acute myeloid leukaemia.
    Br J Haematol. 2025;206:1092-1096.
    PubMed     Abstract available


  9. PRATZ KW
    Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.
    Br J Haematol. 2025;206:1250-1252.
    PubMed     Abstract available


  10. FRERICH C, Li P, Raess PW, Dunlap J, et al
    Landscape of somatic mutations and clonal evolution in NUP98-rearranged adult acute myeloid leukaemia.
    Br J Haematol. 2025;206:1097-1102.
    PubMed     Abstract available


  11. DE BOTTON S, Recher C, Cortes J, Curti A, et al
    Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.
    Br J Haematol. 2025;206:1121-1128.
    PubMed     Abstract available


    March 2025
  12. PERUTELLI F, Boccellato E, Montalbano MC, Catania G, et al
    Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:924-929.
    PubMed     Abstract available


  13. SERAFIN A, Ruocco V, Cellini A, Angotzi F, et al
    Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype.
    Br J Haematol. 2025;206:832-841.
    PubMed     Abstract available


  14. VALTIS YK, Luskin MR
    Better late than never: Delayed asparaginase during induction for acute lymphoblastic leukaemia in adults.
    Br J Haematol. 2025;206:1016-1017.
    PubMed     Abstract available


  15. LAING A, Elmarghany A, Alghaith AA, Gouma A, et al
    Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism.
    Br J Haematol. 2025;206:858-863.
    PubMed     Abstract available


  16. TINAJERO J, Xu S, Ngo D, Li S, et al
    Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes.
    Br J Haematol. 2025;206:868-875.
    PubMed     Abstract available


    February 2025
  17. ZHAO J, Liu TF, Wu KF, Yang LC, et al
    Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups.
    Br J Haematol. 2025 Feb 17. doi: 10.1111/bjh.20011.
    PubMed     Abstract available


  18. CHEN Z, Ren A, Li Y, Shu J, et al
    mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells.
    Br J Haematol. 2025;206:628-643.
    PubMed     Abstract available


  19. LIN CC, Hsu CL, Yao CY, Wang YH, et al
    HOPX as a tumour-suppressive protein in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2025;206:505-516.
    PubMed     Abstract available


  20. GANZEL C, Frisch A, Wolach O, Moshe Y, et al
    CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.
    Br J Haematol. 2025;206:551-555.
    PubMed     Abstract available


  21. GURNARI C, Visconte V
    Dissecting the genomic traits and clinical course of secondary myelodysplastic syndrome following aplastic anaemia: A milestone.
    Br J Haematol. 2025;206:790-791.
    PubMed     Abstract available


  22. ESTELLER M
    Targeting RNA modifications in leukaemia: Epitranscriptomic drugs are the new kids on the block.
    Br J Haematol. 2025;206:785-787.
    PubMed     Abstract available


  23. CHEN X, Gong RZ, Mo LY, Cheng YT, et al
    Hydroxy-wybutosine tRNA modifications as indicators of disease progression and therapeutic targets in leukaemia.
    Br J Haematol. 2025;206:517-530.
    PubMed     Abstract available


    January 2025
  24. SWEET K, Cluzeau T
    Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:61-68.
    PubMed     Abstract available


  25. COSTA A, Scalzulli E, Breccia M
    Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategies.
    Br J Haematol. 2025;206:44-60.
    PubMed     Abstract available


  26. HA TQ, Andresen V, Erikstein BS, Popa M, et al
    Preclinical activity of resazurin in acute myeloid leukaemia.
    Br J Haematol. 2025;206:109-119.
    PubMed     Abstract available


  27. JIANG L, Cheng J, Sun J, Zhang Y, et al
    Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission.
    Br J Haematol. 2025;206:250-262.
    PubMed     Abstract available


  28. VEDI A, Leiter SM, Memon IL, Mahendrayogam A, et al
    Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland.
    Br J Haematol. 2025;206:204-208.
    PubMed     Abstract available


  29. DAVIDS MS, Lin KH, Mohamed AI, Munir T, et al
    Measurable residual disease-driven treatment in first-line chronic lymphocytic leukaemia.
    Br J Haematol. 2025;206:33-43.
    PubMed     Abstract available


  30. TRKA J, Fronkova E
    Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood-Are we there yet?
    Br J Haematol. 2025;206:397-398.
    PubMed     Abstract available


  31. HUANG Q, Jiang X, Wang B, Wu Z, et al
    Gallic acid enhances GVL effects of T cells without exacerbating GVHD after haematopoietic stem cell transplantation.
    Br J Haematol. 2025;206:120-132.
    PubMed     Abstract available


  32. THERON A, Alonso-Saladrigues A, Dapena JL, Lopez-Duarte M, et al
    Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children.
    Br J Haematol. 2025;206:186-194.
    PubMed     Abstract available


  33. COUSSON S, Calvo C, Goldwirt L, Simonin M, et al
    Monocentric experience of venetoclax-based regimen in paediatric refractory and relapsed AML/MDS.
    Br J Haematol. 2025;206:209-214.
    PubMed     Abstract available


    December 2024
  34. FROST EL, Chonat S, Williams KM, Aumann W, et al
    Fatal thrombotic microangiopathy during induction for acute myeloid leukemia: A case report and review of vascular complications in germline GATA2 haploinsufficiency.
    Br J Haematol. 2024 Dec 8. doi: 10.1111/bjh.19935.
    PubMed    


  35. HUGUET F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, et al
    Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
    Br J Haematol. 2024;205:2295-2304.
    PubMed     Abstract available


  36. MORIGUCHI M, Nakamae H, Nishimoto M, Sugita J, et al
    Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;205:2376-2386.
    PubMed     Abstract available


  37. KONDO T
    A new face in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:2131-2133.
    PubMed     Abstract available


  38. PULA AE, Robak T
    The discovery of the RCC1::IRF4 Fusion in CLL patients with t(1;6)(p35.3;p25.2) chromosomal translocation.
    Br J Haematol. 2024;205:2125-2127.
    PubMed     Abstract available


  39. BOUSSI L, Biswas J, Abdel-Wahab O, Stein E, et al
    Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.
    Br J Haematol. 2024;205:2153-2162.
    PubMed     Abstract available


  40. JAYNE S, Lopez C, Put N, Nagel I, et al
    The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion.
    Br J Haematol. 2024;205:2321-2326.
    PubMed     Abstract available


  41. TERUEL-MONTOYA R, Rivera J, Lozano ML
    The importance of genetic variant cleaners: From patient to wet lab and back to clinical practice.
    Br J Haematol. 2024;205:2122-2124.
    PubMed     Abstract available


  42. KAMIYA LJ, Barozzi S, Isidori F, Ganiewich D, et al
    Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis.
    Br J Haematol. 2024;205:2315-2320.
    PubMed     Abstract available


  43. LIU W, Wang C, Ouyang W, Hao J, et al
    Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease.
    Br J Haematol. 2024;205:2228-2233.
    PubMed     Abstract available


  44. ASHOURI K, Hom B, Ginosyan AA, Rahimi Y, et al
    Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy.
    Br J Haematol. 2024;205:2234-2247.
    PubMed     Abstract available


    November 2024
  45. LV M, Yan CH, Ma R, He Y, et al
    Mega-dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study.
    Br J Haematol. 2024;205:1910-1920.
    PubMed     Abstract available


  46. BOULIGNY IM, DiNardo CD
    Oral decitabine-cedazuridine in acute myeloid leukaemia.
    Br J Haematol. 2024;205:1674-1676.
    PubMed     Abstract available


  47. GEISSLER K, Koristek Z, Del Castillo TB, Novak J, et al
    Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
    Br J Haematol. 2024;205:1734-1745.
    PubMed     Abstract available


  48. PHILIP C, Selvarajan S, Nayak L, Jain H, et al
    Impact of the COVID-19 pandemic on treatment of patients with acute myeloid leukaemia in India.
    Br J Haematol. 2024;205:2058-2062.
    PubMed     Abstract available


  49. YANADA M
    Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia.
    Br J Haematol. 2024;205:1672-1673.
    PubMed     Abstract available


  50. MAILLET F, Galimard JE, Borie R, Lainey E, et al
    Haematological features of telomere biology disorders diagnosed in adulthood: A French nationwide study of 127 patients.
    Br J Haematol. 2024;205:1835-1847.
    PubMed     Abstract available


  51. ARIFFIN H
    Incorrigible inflammation.
    Br J Haematol. 2024;205:1679-1680.
    PubMed     Abstract available


  52. CICCONI L, Bisegna M, Gurnari C, Fanciullo D, et al
    Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications.
    Br J Haematol. 2024;205:1727-1733.
    PubMed     Abstract available


  53. SPECTOR LG, de Smith AJ
    Backtracking childhood leukaemia to birth: A battle of addition.
    Br J Haematol. 2024;205:1670-1671.
    PubMed     Abstract available


  54. YANG YT, Yao CY, Kao CJ, Chiu PJ, et al
    Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy.
    Br J Haematol. 2024;205:1751-1764.
    PubMed     Abstract available


  55. XU N, Dao FT, Shi ZY, Sun K, et al
    WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia.
    Br J Haematol. 2024;205:1848-1859.
    PubMed     Abstract available


  56. ZHU Q, Nambiar R, Schultz E, Gao X, et al
    Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:1889-1898.
    PubMed     Abstract available


  57. BARDINI M, Fazio G, Abascal LC, Meyer C, et al
    Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:1883-1888.
    PubMed     Abstract available


  58. WEINBERGEROVA B, Mayer J, Kabut T, Sperr WR, et al
    Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.
    Br J Haematol. 2024;205:1746-1750.
    PubMed     Abstract available


    October 2024
  59. YOSHIMITSU M, Tanaka T, Nakano N, Kato K, et al
    Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2024 Oct 19. doi: 10.1111/bjh.19835.
    PubMed     Abstract available


  60. NAKAMURA M, Chonabayashi K, Narita M, Matsumura Y, et al
    Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs.
    Br J Haematol. 2024;205:1430-1443.
    PubMed     Abstract available


  61. GHOSH N, Manzoor BS, Fakhri B, Emechebe N, et al
    Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.
    Br J Haematol. 2024;205:1395-1403.
    PubMed     Abstract available


  62. GAO MY, Georgiou A, Lin VS, Jahja M, et al
    Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications.
    Br J Haematol. 2024;205:1389-1394.
    PubMed     Abstract available


  63. MEHTA P, Campbell V, Maddox J, Floisand Y, et al
    CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
    Br J Haematol. 2024;205:1326-1336.
    PubMed     Abstract available


  64. ANASTASOPOULOU S, Swann G, Andres-Jensen L, Attarbaschi A, et al
    Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study.
    Br J Haematol. 2024;205:1450-1459.
    PubMed     Abstract available


    September 2024
  65. NARESH KN
    Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions.
    Br J Haematol. 2024 Sep 10. doi: 10.1111/bjh.19754.
    PubMed     Abstract available


  66. HEI Z, Yang S, Ouyang G, Hanna J, et al
    Targeting the redox vulnerability of acute myeloid leukaemia cells with a combination of auranofin and vitamin C.
    Br J Haematol. 2024;205:1017-1030.
    PubMed     Abstract available


  67. LEBLANC FR, Breese EH, Burns KC, Chang EK, et al
    Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.
    Br J Haematol. 2024;205:1055-1066.
    PubMed     Abstract available


  68. HUANG C, Jia Y, Yang J, Cai Y, et al
    Azacitidine combined with interferon-alpha for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.
    Br J Haematol. 2024;205:1067-1076.
    PubMed     Abstract available


  69. GOVER-PROAKTOR A, Leshem-Lev D, Winograd-Katz S, Partouche S, et al
    Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia.
    Br J Haematol. 2024;205:1011-1016.
    PubMed     Abstract available


  70. KUGLER E, Cohen I, Amitai I, Ram R, et al
    Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;205:932-941.
    PubMed     Abstract available


  71. KUHN MWM, Ganser A
    The Menin story in acute myeloid leukaemia-The road to success.
    Br J Haematol. 2024;205:812-814.
    PubMed     Abstract available


  72. ZHAO S, Wang J, Lou Y, Huang X, et al
    Clinical characteristics of acute myeloid leukaemia patients with a large number of azurophilic granules: A single-centre retrospective study.
    Br J Haematol. 2024;205:924-931.
    PubMed     Abstract available


  73. ROBERTSON HF, Milojkovic D, Butt N, Byrne J, et al
    Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy.
    Br J Haematol. 2024;205:947-955.
    PubMed     Abstract available


  74. MARCHAND T, Pastoret C, Damaj G, Lebouvier A, et al
    Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.
    Br J Haematol. 2024;205:915-923.
    PubMed     Abstract available


    August 2024
  75. GLANZMANN J, Kalberer C, Bonadies N, Colucci G, et al
    Plasma cells with Auer-rod-like inclusions in a patient with MGUS and acute myeloid leukaemia with NPM1 mutation.
    Br J Haematol. 2024;205:401-402.
    PubMed    


  76. YANG F, Ren Q, Zu Y, Gui R, et al
    Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;205:645-652.
    PubMed     Abstract available


  77. TRINQUAND A, Betts DR, Rooney S, Storey L, et al
    MRD-risk stratification mitigates TLX3 prognostic impact in paediatric T-cell acute lymphoblastic leukaemia: A national cohort analysis.
    Br J Haematol. 2024;205:729-732.
    PubMed    


  78. CHEN C, Li J, Chen Y, Gao Q, et al
    The correlation of asparaginase enzyme activity levels after PEG-asparaginase administration with clinical characteristics and adverse effects in Chinese paediatric patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:624-633.
    PubMed     Abstract available


  79. ZHU W, Ding Y, Huang W, Guo N, et al
    Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI-503 against MLL::AF9-driven acute myeloid leukaemia.
    Br J Haematol. 2024;205:568-579.
    PubMed     Abstract available


  80. GRADY E, Biswas S, Dias T, McCarthy P, et al
    A novel TCF3::PIK3R1 fusion linked to decreased PI3K-AKT signalling activity in paediatric B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:738-741.
    PubMed    


  81. OTHMAN T, Koller P, Pourhassan H, Agrawal V, et al
    Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:711-715.
    PubMed    


  82. WANG S, Liu Y, Zhao X, Wang X, et al
    RUNX1::ETO and CBFbeta::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
    Br J Haematol. 2024;205:552-567.
    PubMed     Abstract available


  83. TANG FF, Duan WB, Liu XH, Lu SY, et al
    A complete oral regimen for induction therapy of patients with high-risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy.
    Br J Haematol. 2024;205:510-516.
    PubMed     Abstract available


  84. NGUYEN-KHAC F, Baron M, Guieze R, Feugier P, et al
    Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
    Br J Haematol. 2024;205:495-502.
    PubMed     Abstract available


  85. XU X, Huang Z, Ding C, Deng S, et al
    STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:517-528.
    PubMed     Abstract available


  86. BOTTEN GA, Zhang Y, Fuda F, Koduru P, et al
    T/myeloid mixed phenotype acute leukaemia harbouring TLX3::BCL11B with TLX3 activation.
    Br J Haematol. 2024;205:607-612.
    PubMed     Abstract available


    July 2024
  87. ALLEN B, Savoy L, Ryabinin P, Bottomly D, et al
    Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia.
    Br J Haematol. 2024;205:207-219.
    PubMed     Abstract available


  88. RONNACKER J, Urbahn MA, Reicherts C, Kolloch L, et al
    Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia.
    Br J Haematol. 2024;205:280-290.
    PubMed     Abstract available


  89. JIMENEZ-VICENTE C, Charry P, Castano-Diez S, Guijarro F, et al
    Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.
    Br J Haematol. 2024;205:256-267.
    PubMed     Abstract available


  90. PICHLER H, Sedlacek P, Meisel R, Beier R, et al
    Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group.
    Br J Haematol. 2024;205:268-279.
    PubMed     Abstract available


  91. TAURINO G, Dander E, Chiu M, Pozzi G, et al
    Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP-ALL cell survival and a potential therapeutic target.
    Br J Haematol. 2024;205:175-188.
    PubMed     Abstract available


  92. WANG HY, Louis HMS, Costello CL, Murray SS, et al
    A CD10-negative adult B-lymphoblastic leukaemia with amplification of KMT2A without rearrangement: A case report and review of the English literature.
    Br J Haematol. 2024;205:364-367.
    PubMed    


  93. DOURTHE ME, Yakouben K, David A, Thouvenin S, et al
    Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2024;205:373-377.
    PubMed    


  94. JEN WY, Kantarjian H, Kadia TM, DiNardo CD, et al
    Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
    Br J Haematol. 2024;205:30-47.
    PubMed     Abstract available


  95. SERAFIN A, Cellini A, Cavarretta CA, Ruocco V, et al
    Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens.
    Br J Haematol. 2024;205:189-193.
    PubMed     Abstract available


  96. ZHANG X, Zhong Y, Liu L, Suo S, et al
    MN1::ETV6-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report.
    Br J Haematol. 2024;205:352-355.
    PubMed    


  97. IYENGAR L, Fong CY, Prakash S, Chong AH, et al
    Cutaneous involvement in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;205:11.
    PubMed    


  98. POURHASSAN H, Zhang J, Tinajero J, Pullarkat V, et al
    Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
    Br J Haematol. 2024;205:158-165.
    PubMed     Abstract available


    June 2024
  99. XU J, Peng J, Sun S, Wang D, et al
    Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:2301-2318.
    PubMed     Abstract available


  100. DELGADO J
    InsT-ALLing CD7 chimeric antigen receptors before transplantation.
    Br J Haematol. 2024;204:2155-2156.
    PubMed     Abstract available


  101. ENJETI AK, Fogler WE, Smith TAG, Lincz LF, et al
    Combining 5-azacitidine with the E-selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia.
    Br J Haematol. 2024;204:2264-2274.
    PubMed     Abstract available


  102. ORTIZ ROJAS CA, Pereira-Martins DA, Bellido More CC, Sternadt D, et al
    A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction.
    Br J Haematol. 2024;204:2287-2300.
    PubMed     Abstract available


  103. LIU H, Wu K, Hu W, Chen X, et al
    Immunophenotypic clustering in paediatric acute myeloid leukaemia.
    Br J Haematol. 2024;204:2275-2286.
    PubMed     Abstract available


  104. MAO S, Lin Y, Qin X, Miao Y, et al
    Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML.
    Br J Haematol. 2024;204:2332-2341.
    PubMed     Abstract available


  105. JEN WY, Sasaki K, Loghavi S, Wang SA, et al
    Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
    Br J Haematol. 2024;204:2259-2263.
    PubMed     Abstract available


  106. KINSELLA FAM, Maroto MAL, Loke J, Craddock C, et al
    Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia.
    Br J Haematol. 2024;204:2173-2183.
    PubMed     Abstract available


  107. ROLLIG C, Schliemann C, Ruhnke L, Fransecky L, et al
    Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
    Br J Haematol. 2024;204:2254-2258.
    PubMed     Abstract available


  108. ONIDA F, Gras L, Ge J, Koster L, et al
    Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT.
    Br J Haematol. 2024;204:2365-2377.
    PubMed     Abstract available


  109. HARROP S, Nguyen PC, Robinson S, Nguyen T, et al
    Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications.
    Br J Haematol. 2024;204:2492-2495.
    PubMed    


  110. BARNBROCK A, Moricke A, Barbaric D, Jones N, et al
    Pneumocystis jirovecii pneumonia in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.
    Br J Haematol. 2024;204:2319-2323.
    PubMed     Abstract available


  111. DONG Q, Wang Y, Xiu Y, Wu X, et al
    Unveiling myeloid transformation: T-LGLL with eosinophilia masking myeloid-associated STAT5B mutation culminating in AML.
    Br J Haematol. 2024;204:2487-2491.
    PubMed    


  112. BAUCH T, Hempel G
    Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:2324-2331.
    PubMed     Abstract available


    May 2024
  113. RUPAKUMAR T, Sankar A, Vijayasekharan K, Varikkattu Rajendran P, et al
    Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India.
    Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19559.
    PubMed     Abstract available


  114. BALDUZZI A
    The CAR T-cell race: The rules of the game.
    Br J Haematol. 2024;204:1579-1581.
    PubMed     Abstract available


  115. ZHANG X, Tao C, Long F
    Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with hydroxycarbamide.
    Br J Haematol. 2024;204:1569-1570.
    PubMed    


  116. MISHRA AK, Burridge S, Espuelas MO, O'Reilly M, et al
    Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1687-1696.
    PubMed     Abstract available


  117. KRIEGER E, Qayyum R, Toor A
    Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
    Br J Haematol. 2024;204:1935-1943.
    PubMed     Abstract available


  118. LEBECQUE B, Besombes J, Dannus LT, De Antonio M, et al
    Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
    Br J Haematol. 2024;204:1872-1881.
    PubMed     Abstract available


  119. JO T, Ueda T, Akahoshi Y, Kondo T, et al
    First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1913-1919.
    PubMed     Abstract available


  120. BOUKOUACI W, Rivera-Franco MM, Volt F, Lajnef M, et al
    HLA peptide-binding pocket diversity modulates immunological complications after cord blood transplant in acute leukaemia.
    Br J Haematol. 2024;204:1920-1934.
    PubMed     Abstract available


  121. BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
    The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
    Br J Haematol. 2024;204:1649-1659.
    PubMed     Abstract available


  122. LOH Z, Ashby M, Van Veldhuizen E, Li W, et al
    Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
    Br J Haematol. 2024;204:1732-1739.
    PubMed     Abstract available


    April 2024
  123. HUO W, Gao L, Song K, Huang J, et al
    Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China.
    Br J Haematol. 2024 Apr 25. doi: 10.1111/bjh.19481.
    PubMed     Abstract available


  124. CAO XY, Zhang JP, Lu Y, Zhao YL, et al
    A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen r
    Br J Haematol. 2024 Apr 13. doi: 10.1111/bjh.19445.
    PubMed     Abstract available


  125. LIU HC, Huang YJ, Jaing TH, Wu KH, et al
    Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1(plus) and Day 15 MRD positivity.
    Br J Haematol. 2024;204:1344-1353.
    PubMed     Abstract available


  126. BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
    Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1367-1374.
    PubMed     Abstract available


  127. CHEN X, Li J, Yu L, Hu W, et al
    High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
    Br J Haematol. 2024;204:1354-1366.
    PubMed     Abstract available


  128. MOSQUERA ORGUEIRA A, Perez Encinas MM, Diaz Varela N, Wang YH, et al
    Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
    Br J Haematol. 2024;204:1529-1535.
    PubMed     Abstract available


  129. STENTOFT J
    The Mozart effect in chronic myeloid leukaemia.
    Br J Haematol. 2024;204:1139-1140.
    PubMed     Abstract available


  130. PATEL SA
    The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
    Br J Haematol. 2024;204:1137-1138.
    PubMed     Abstract available


  131. ZHANG T, Zhang Y, Zhou M, Zhang Z, et al
    Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:1402-1413.
    PubMed     Abstract available


  132. ALCAZER V, Morisset S, Rea D, Legros L, et al
    Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
    Br J Haematol. 2024;204:1536-1539.
    PubMed    


  133. JOHNSON IM, Karrar O, Rana M, Iftikhar M, et al
    Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
    Br J Haematol. 2024;204:1232-1237.
    PubMed     Abstract available


  134. NACHMIAS B, Aumann S, Haran A, Schimmer AD, et al
    Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
    Br J Haematol. 2024;204:1146-1158.
    PubMed     Abstract available


  135. ZUCENKA A, Griskevicius L
    Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:1227-1231.
    PubMed     Abstract available


  136. SUWANNAYING K, Ong AA, Dhaduk R, Pei D, et al
    Quantitative computed tomography analysis of body composition changes in paediatric patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1335-1343.
    PubMed     Abstract available


  137. FIEDLER W
    Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy.
    Br J Haematol. 2024;204:1135-1136.
    PubMed     Abstract available


  138. LIANG P, Xie Y, Liu Z, Wang D, et al
    Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2024;204:1219-1226.
    PubMed     Abstract available


  139. ROY MOULIK N, Keerthivasagam S, Pandey A, Agiwale J, et al
    Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
    Br J Haematol. 2024;204:1249-1261.
    PubMed     Abstract available


  140. MADERO-MARROQUIN R, DuVall AS, Saygin C, Wang P, et al
    Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
    Br J Haematol. 2024;204:1238-1242.
    PubMed     Abstract available


  141. LIGIA S, Passucci M, Assanto GM, D'Elia GM, et al
    Early clearance of hairy cell leukaemia in the bone marrow after first-line treatment with cladribine predicts a favourable outcome.
    Br J Haematol. 2024;204:1288-1292.
    PubMed     Abstract available


    March 2024
  142. LARIBI K, Poulain S, Willems L, Merabet F, et al
    Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2024 Mar 19. doi: 10.1111/bjh.19409.
    PubMed     Abstract available


  143. NG HL, Robinson ME, May PC, Innes AJ, et al
    Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
    Br J Haematol. 2024;204:945-958.
    PubMed     Abstract available


  144. SUN H, Zhu Y, Li J, Zhao L, et al
    CSF3R P733T is a deleterious germline variant in acute leukaemia showing gain-of-function-like T618I mutation.
    Br J Haematol. 2024;204:e31-e33.
    PubMed    


  145. SHIMONY S, Chen EC
    Tri-ing to decipher trisomy AML.
    Br J Haematol. 2024;204:751-752.
    PubMed     Abstract available


  146. TAN JY, Yeo YH, Tan MC, Chavez JC, et al
    Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy.
    Br J Haematol. 2024;204:1114-1117.
    PubMed    


  147. ZHAO HG
    Should oligomonocytic CMML be classified as an independent disease entity?
    Br J Haematol. 2024;204:749-750.
    PubMed     Abstract available


  148. LAM SSY, Tsui SP, Fung CY, Saw NY, et al
    Distinct karyotypic and mutational landscape in trisomy AML.
    Br J Haematol. 2024;204:939-944.
    PubMed     Abstract available


  149. COPLAND M, Ariti C, Thomas IF, Upton L, et al
    A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
    Br J Haematol. 2024;204:871-876.
    PubMed     Abstract available


  150. CASTANO-DIEZ S, Pomares H, Esteban D, Guijarro F, et al
    Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
    Br J Haematol. 2024;204:892-897.
    PubMed     Abstract available


  151. LU Q, Qu W, Wen Y, Ke P, et al
    Single-cell RNA-seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML.
    Br J Haematol. 2024;204:1100-1104.
    PubMed    


  152. RAVANDI F, Dohner H, Wei AH, Montesinos P, et al
    Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
    Br J Haematol. 2024;204:877-886.
    PubMed     Abstract available


  153. MONTALBAN-BRAVO G, Jabbour E, Borthakur G, Kadia T, et al
    Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
    Br J Haematol. 2024;204:898-909.
    PubMed     Abstract available


  154. CHEN N, Pan J, Zhou Y, Mao L, et al
    Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:861-870.
    PubMed     Abstract available


    February 2024
  155. COSTA A, Breccia M
    How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
    Br J Haematol. 2024;204:434-448.
    PubMed     Abstract available


  156. PARDANANI A, Reichard K, Tefferi A
    Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
    Br J Haematol. 2024;204:402-414.
    PubMed     Abstract available


  157. FUJI S, Yuda S, Tada Y, Kano M, et al
    A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL.
    Br J Haematol. 2024;204:e25-e27.
    PubMed    


  158. WANG Z, Fan Z, Wu Z, Xuan L, et al
    PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:628-637.
    PubMed     Abstract available


  159. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
    Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;204:561-565.
    PubMed     Abstract available


  160. NYQUIST OE, Dalgaard J, Spetalen S, Torkildsen S, et al
    Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML.
    Br J Haematol. 2024;204:724-729.
    PubMed    


  161. NARDOZZA AM, Guarnera L, Travaglini S, Ottone T, et al
    Characterization of a novel IDH2-R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation.
    Br J Haematol. 2024;204:719-723.
    PubMed    


  162. RAMAMOORTHY S, Lebrecht D, Schanze D, Schanze I, et al
    Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
    Br J Haematol. 2024;204:595-605.
    PubMed     Abstract available


  163. MARK C, Meshinchi S, Joyce B, Gibson B, et al
    Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
    Br J Haematol. 2024;204:576-584.
    PubMed     Abstract available


  164. SHEN Y, Freeman JA, Kerridge I, Downe P, et al
    Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL.
    Br J Haematol. 2024;204:487-491.
    PubMed     Abstract available


  165. BAI L, Zhang ZX, Hu GH, Cheng YF, et al
    Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre.
    Br J Haematol. 2024;204:585-594.
    PubMed     Abstract available


    January 2024
  166. MIYASHITA N, Onozawa M, Matsukawa T, Mori A, et al
    Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
    Br J Haematol. 2024 Jan 18. doi: 10.1111/bjh.19292.
    PubMed    


  167. NAVRKALOVA V, Plevova K, Radova L, Porc J, et al
    Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naive CLL patients.
    Br J Haematol. 2024;204:240-249.
    PubMed     Abstract available


  168. HASSELBALCH HC, Skov V, Kjaer L, Larsen MK, et al
    Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
    Br J Haematol. 2024;204:16-18.
    PubMed     Abstract available


  169. GJERTSEN BT
    How to discover the exceptional venetoclax responders in AML/MDS?
    Br J Haematol. 2024;204:14-15.
    PubMed    


  170. GESTRICH CK, De Lancy SJ, Kresak A, Meyerson H, et al
    IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:229-239.
    PubMed     Abstract available


  171. BARON F, Nagler A, Galimard JE, Sanz J, et al
    Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
    Br J Haematol. 2024;204:250-259.
    PubMed     Abstract available


  172. DE CASTRO FA, Mehdipour P, Chakravarthy A, Ettayebi I, et al
    Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
    Br J Haematol. 2024;204:206-220.
    PubMed     Abstract available


  173. NANAA A, He R, Foran JM, Badar T, et al
    Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
    Br J Haematol. 2024;204:171-176.
    PubMed     Abstract available


  174. MURPHY EL
    HTLV-1 and blood donation.
    Br J Haematol. 2024;204:29-30.
    PubMed     Abstract available


    December 2023
  175. HOKLAND P, Fernandez II, Freeman SD, Gjertsen BT, et al
    AML in the elderly-A global view.
    Br J Haematol. 2023;203:760-773.
    PubMed    


  176. WU JF, Abid H, Szabo A, Abid MB, et al
    Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
    Br J Haematol. 2023;203:e117-e120.
    PubMed    


  177. HERRITY E, Pereira MP, Kim DDH
    Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions.
    Br J Haematol. 2023;203:722-735.
    PubMed     Abstract available


  178. MAHDI D, O'Nions J, Raj K, Baker R, et al
    Managing molecular relapse of acute myeloid leukaemia in early pregnancy: Is a watch and wait approach reasonable?
    Br J Haematol. 2023;203:e114-e116.
    PubMed    


  179. QI P, Wang L, Li H, Wu Y, et al
    Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: A single-centre experience.
    Br J Haematol. 2023;203:892-895.
    PubMed    


  180. PERUSINI MA, Novitzky-Basso I, Atenafu EG, Forrest D, et al
    Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
    Br J Haematol. 2023;203:781-791.
    PubMed     Abstract available


  181. CHIRIAC R, Humbert C, Mejri A, Debliquis A, et al
    Charcot-Leyden crystals in acute myeloid leukaemia associated with basophilia.
    Br J Haematol. 2023;203:699-700.
    PubMed    


    November 2023
  182. NG JY, Joshi M, Choi P
    Frequency and outcomes of obinutuzumab-induced thrombocytopenia.
    Br J Haematol. 2023;203:668-672.
    PubMed     Abstract available


  183. BORLENGHI E, Roccaro AM, Cattaneo C
    Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients.
    Br J Haematol. 2023;203:504-506.
    PubMed     Abstract available


  184. REYNOLDS G, Urbancic KF, Fong CY, Trubiano JA, et al
    Invasive fungal infection following venetoclax and posaconazole co-administration.
    Br J Haematol. 2023;203:593-598.
    PubMed     Abstract available


  185. OCADLIKOVA D, Lussana F, Fracchiolla N, Bonifacio M, et al
    Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
    Br J Haematol. 2023;203:637-650.
    PubMed     Abstract available


  186. BOOTH E, Backx M, Joshi A, Nizami H, et al
    Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
    Br J Haematol. 2023;203:499-500.
    PubMed    


  187. DONNETTE M, Hamimed M, Ciccolini J, Sicard G, et al
    Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
    Br J Haematol. 2023;203:625-636.
    PubMed     Abstract available


  188. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Li Z, Hammond D, et al
    Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
    Br J Haematol. 2023;203:581-592.
    PubMed     Abstract available


  189. APOLITO V, Arrigo G, Vasseur L, Olivi M, et al
    Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.
    Br J Haematol. 2023;203:e98-e101.
    PubMed    


    October 2023
  190. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
    The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
    PubMed     Abstract available


  191. PAN X, Chang Y, Ruan G, Wei F, et al
    Prognostic impact of FLT3-ITD mutation on NPM1(+) acute myeloid leukaemia patients and related molecular mechanisms.
    Br J Haematol. 2023;203:212-223.
    PubMed     Abstract available


  192. MAHDI D, Spiers J, Rampotas A, Polverelli N, et al
    Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
    Br J Haematol. 2023;203:169-181.
    PubMed     Abstract available


  193. SEVERIN F, Mouawad N, Ruggeri E, Visentin A, et al
    Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness.
    Br J Haematol. 2023;203:224-236.
    PubMed     Abstract available


  194. TRAVAGLINI S, Gurnari C, Antonelli S, Marchesi F, et al
    Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept.
    Br J Haematol. 2023;203:327-330.
    PubMed    


  195. EADIE LN, Rehn JA, Schutz CE, Heatley SL, et al
    Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling.
    Br J Haematol. 2023;203:282-287.
    PubMed     Abstract available


    September 2023
  196. BRECCIA M, Saglio G
    Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
    Br J Haematol. 2023;202:1087-1088.
    PubMed     Abstract available


  197. HADDAD FG, Kourie HR, Saleh K
    Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2023;202:1084-1086.
    PubMed     Abstract available


  198. IRANI YD, Hughes A, Kok CH, Clarson J, et al
    Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
    Br J Haematol. 2023;202:1127-1136.
    PubMed     Abstract available


  199. FENG H, Fu Y, Cui Z, Zhou M, et al
    Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
    Br J Haematol. 2023;202:1178-1191.
    PubMed     Abstract available


  200. PESCHKE JC, Bergmann R, Mehnert M, Gonzalez Soto KE, et al
    FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
    Br J Haematol. 2023;202:1137-1150.
    PubMed     Abstract available


  201. PASTORE F, Gittinger H, Raab S, Tschuri S, et al
    Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
    Br J Haematol. 2023;202:1165-1177.
    PubMed     Abstract available


  202. XIE M, Lu Y, Ouyang G, Li X, et al
    Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
    Br J Haematol. 2023;202:1119-1126.
    PubMed     Abstract available


  203. MATSUMOTO K, Kakazu N, Imataki O, Kondo A, et al
    Hairy cell leukaemia with an IGH-BRAF fusion gene.
    Br J Haematol. 2023;202:e67-e70.
    PubMed    


  204. BELHADJ M, Burroni B, Kosmider O, Willems L, et al
    Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study.
    Br J Haematol. 2023;202:e50-e53.
    PubMed    


    August 2023
  205. KUSUDA M, Nakasone H, Yoshimura K, Okada Y, et al
    Gene expression and TCR amino acid sequences selected by HLA-A02:01-restricted CTLs specific to HTLV-1 in ATL patients.
    Br J Haematol. 2023;202:578-588.
    PubMed     Abstract available


  206. LOKE J, Upasani V, Gaskell C, Fox S, et al
    Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
    Br J Haematol. 2023;202:498-503.
    PubMed     Abstract available


  207. SARTOR C, Brunetti L, Audisio E, Cignetti A, et al
    A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
    Br J Haematol. 2023;202:599-607.
    PubMed     Abstract available


  208. BORRILL R, Poulton K, Kusyk L, Routledge A, et al
    Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8(+) T-cell expansion, significant cytokine release syndrome and induction of disease remission.
    Br J Haematol. 2023;202:589-598.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.